The current understanding on the impact of KRAS on colorectal cancer

KRAS (kirsten rat sarcoma viral oncogene) is a member of the RAS family. KRAS mutations are one of most dominant mutations in colorectal cancer (CRC). The impact of KRAS mutations on the prognosis and survival of CRC patients drives many research studies to explore potential therapeutics or target t...

Full description

Saved in:
Bibliographic Details
Published inBiomedicine & pharmacotherapy Vol. 140; p. 111717
Main Authors Meng, Mingjing, Zhong, Keying, Jiang, Ting, Liu, Zhongqiu, Kwan, Hiu Yee, Su, Tao
Format Journal Article
LanguageEnglish
Published Elsevier Masson SAS 01.08.2021
Elsevier
Subjects
Colorectal cancer
KRAS
Mutation
Therapy
Therapy
GTP
HRM
FDA
SAR
Colorectal cancer
HR
EGFR
TTR
FFPE
MSI-low
GAPs
IGF-1R
OS
DSS
VEGF
PDE4
GEFs
TCGA
APC
CRC
KRAS
Grb2
Mutation
GAPDH
Online AccessGet full text

Cover

More Information
Summary:KRAS (kirsten rat sarcoma viral oncogene) is a member of the RAS family. KRAS mutations are one of most dominant mutations in colorectal cancer (CRC). The impact of KRAS mutations on the prognosis and survival of CRC patients drives many research studies to explore potential therapeutics or target therapy for the KRAS mutant CRC. This review summarizes the current understanding of the pathological consequences of the KRAS mutations in the development of CRC; and the impact of the mutations on the response and the sensitivity to the current front-line chemotherapy. The current therapeutic strategies for treating KRAS mutant CRC, the difficulties and challenges will also be discussed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0753-3322
1950-6007
DOI:10.1016/j.biopha.2021.111717